RxPG News Feed for RxPG News

Medical Research Health Special Topics World
 Asian Health
 Food & Nutrition
 Men's Health
 Mental Health
 Occupational Health
 Public Health
 Sleep Hygiene
 Women's Health
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 World Healthcare
   Latest Research
 Alternative Medicine
  Clinical Trials
  Myocardial Infarction
 Clinical Trials
 Infectious Diseases
 Sports Medicine
   Medical News
 Awards & Prizes
   Special Topics
 Odd Medical News

Last Updated: Oct 11, 2012 - 10:22:56 PM
CHF Channel

subscribe to CHF newsletter
Latest Research : Cardiology : CHF

   EMAIL   |   PRINT
Gene therapy trial for advanced heart failure promising

Nov 12, 2008 - 1:29:29 PM
The phase-II randomized, double-blind, placebo-controlled clinical trial will compare the therapy at two- or three-dose levels with placebo.

[RxPG] Washington, Nov 11 - The first clinical trial of gene therapy for advanced heart failure has shown promising results.

It is a technique for correcting defective genes responsible for the disease by inserting genes into a patient's cells and tissues.

Seven of nine patients given the drug showed improvements over six months in several areas. Two patients did not show improvements.

This approach under CUPID's phase-I trials was shown to have an acceptable safety profile, validated by an independent safety committee and by study investigators.

CUPID stands for calcium up-regulation by percutaneous administration of gene therapy in cardiac disease.

Enrolled patients underwent cardiac catheterisation, to introduce an engineered gene to stimulate enzyme production to help the heart pump more efficiently.

'We are encouraged that this therapy has the potential to help patients with advanced heart failure,' said Donna Mancini, the study's principal investigator and professor of medicine at Columbia University.

More than five million people in the US have heart failure. Patients with severe form of the disease have trouble breathing because the heart muscle is not strong enough to pump fluid out of their lungs.

Approximately 70 percent die of the disease within 10 years, and the five-year survival rate is less than 50 percent.

New York-Presbyterian Hospital / Columbia University Medical Centre was the first to offer the therapy in the New York City area.

The hospital is now recruiting 46 patients for the Phase II CUPID trial to further assess safety and effectiveness in patients with advanced heart failure, said a Columbia press release.

The phase-II randomized, double-blind, placebo-controlled clinical trial will compare the therapy at two- or three-dose levels with placebo.

Data from Phase I trial were presented at the American Heart Association - Scientific Sessions in New Orleans.

Advertise in this space for $10 per month. Contact us today.

Related CHF News
T-tubule disruption occurs before decline in heart function detectable
New technology to identify compounds that triggers heart failure
Arousal disorder in patients with cardiac failure?
Exercise improves life for heart failure patients
Gene therapy trial for advanced heart failure promising
Longer anthracycline therapy reduces heart failure in adult cancer patients
Seven-point system gauges seriousness of heart failure in elderly
Famotidine may help to slow progression of chronic heart failure
Ilk gene underlies heart failure
Nocturnal Hypertension Increase Congestive Heart Failure Risk

Subscribe to CHF Newsletter

Enter your email address:

For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

Contact us

RxPG Online



    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)